Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30540779 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ATDP1NPSR1 | |
| SCHEMBL20089295 | 0.82 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ATDP1NPSR1 | |
| SCHEMBL22366841 | 0.78 | MEN1 (0.37) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL27215175 | 0.78 | POLB (0.35) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL24558216 | 0.74 | MEN1 (0.37) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL16856866 | 0.74 | MEN1 (0.37) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL18299236 | 0.74 | CCR4 (0.36) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL18299570 | 0.74 | MEN1 (0.41) | ALDH1A1MEN1KMT2ATDP1NPSR1 | |
| Formamide SCHEMBL28985269 | 0.73 | — | — | |
| Formic Acid SCHEMBL27666747 | 0.73 | KDM4E (0.32) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368666-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12441707-B2 | Indazole compounds | TYRA BIOSCIENCES, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4547656-A1 | INDAZOLE COMPOUNDS | Tyra Biosciences, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240316022-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2016200851-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| CN-1332743-A | Cell adhesion-inhibiting antinflammatory compounds | ABBOTT CO (US) | 2002-01-23 | — | — | CN | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316022-A1 | INDAZOLE COMPOUNDS | FGFR1, FGFR3, FGFR2 | ALDH1A1 612/4885MEN1 3235/4885KMT2A 2751/4885 |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | ALDH1A1 153/4885MEN1 4064/4885KMT2A 4783/4885 |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | ALDH1A1 1246/4885MEN1 3245/4885KMT2A 1922/4885 |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | ALDH1A1 1246/4885MEN1 3245/4885KMT2A 1922/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | ALDH1A1 4290/4885MEN1 650/4885KMT2A 4041/4885 |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | ALDH1A1 1246/4885MEN1 3245/4885KMT2A 1922/4885 |
| US-20250368666-A1 | INDAZOLE COMPOUNDS | FGFR1, FGFR3, FGFR2 | ALDH1A1 612/4885MEN1 3235/4885KMT2A 2751/4885 |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | ALDH1A1 1246/4885MEN1 3245/4885KMT2A 1922/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | ALDH1A1 153/4885MEN1 4064/4885KMT2A 4783/4885 |
| US-12441707-B2 | Indazole compounds | BRCA1, IDH2, TP53 | ALDH1A1 148/4885MEN1 1624/4885KMT2A 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.